{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:11:14Z","timestamp":1791277874036,"version":"4.1.0"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The prevalence of extensively drug-resistant tuberculosis (XDR-TB), defined as TB that is resistant to isoniazid, rifampin, fluoroquinolones, and aminoglycosides, is rising worldwide. The extent of\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            resistance to fluoroquinolones depends on the mutation in the DNA gyrase, the only target of fluoroquinolones. The MIC of moxifloxacin, the most active fluoroquinolone against\n            <jats:italic>M. tuberculosis<\/jats:italic>\n            , may be lower than its peak serum level for some ofloxacin-resistant strains of\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            . Therefore, if the MIC of moxifloxacin is lower than its peak serum level, it may be effective against XDR-TB. Our objective was to determine the efficacy of moxifloxacin in treating ofloxacin-resistant TB. We selected isogenic fluoroquinolone-resistant mutants of\n            <jats:italic>M. tuberculosis<\/jats:italic>\n            H37Rv\n            <jats:italic>in vivo<\/jats:italic>\n            . We infected Swiss mice with either wild-type H37Rv or one of three mutant strains with different MICs that are commonly seen in clinical practice. The MICs of the mutant strains ranged from below to above the peak moxifloxacin level seen in humans (3 \u03bcg\/ml). Each mouse was treated with one of four moxifloxacin doses for 1 month. Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0.5 \u03bcg\/ml), when the standard dose was doubled. Moxifloxacin reduced mortality in mice infected with mutant strain GyrA A90V with an intermediate MIC (2 \u03bcg\/ml). However, it had no impact on the mutant strain GyrA D94G with the highest MIC (4 \u03bcg\/ml). Our study underscores current WHO recommendations to use moxifloxacin when there is resistance to early-generation fluoroquinolones such as ofloxacin, restricting this recommendation to strains with moxifloxacin MICs of less than or equal to 2 \u03bcg\/ml.\n          <\/jats:p>","DOI":"10.1128\/aac.00968-10","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T02:30:38Z","timestamp":1283221838000},"page":"4765-4771","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":66,"title":["Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model"],"prefix":"10.1128","volume":"54","author":[{"given":"Julien","family":"Poissy","sequence":"first","affiliation":[{"name":"UPMC Universite\u0301 Paris 06, ER5, EA 1541, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75005 Paris, France"},{"name":"Service Universitaire de Maladies Infectieuses et Tropicales, Centre Hospitalier Gustave Dron, 59200 Tourcoing, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Aubry","sequence":"additional","affiliation":[{"name":"UPMC Universite\u0301 Paris 06, ER5, EA 1541, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75005 Paris, France"},{"name":"AP-HP, Ho\u0302pital Pitie\u0301-Salpe\u0302trie\u0300re, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75013 Paris, France"},{"name":"Centre National de Re\u0301fe\u0301rence des Mycobacte\u0301ries et de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fernandez","sequence":"additional","affiliation":[{"name":"AP-HP, Ho\u0302pital Pitie\u0301-Salpe\u0302trie\u0300re, Service Pharmacie-Pharmacocine\u0301tique, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Catherine","family":"Lott","sequence":"additional","affiliation":[{"name":"AP-HP, Ho\u0302pital Pitie\u0301-Salpe\u0302trie\u0300re, Service Pharmacie-Pharmacocine\u0301tique, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Chauffour","sequence":"additional","affiliation":[{"name":"UPMC Universite\u0301 Paris 06, ER5, EA 1541, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75005 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jarlier","sequence":"additional","affiliation":[{"name":"UPMC Universite\u0301 Paris 06, ER5, EA 1541, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75005 Paris, France"},{"name":"AP-HP, Ho\u0302pital Pitie\u0301-Salpe\u0302trie\u0300re, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75013 Paris, France"},{"name":"Centre National de Re\u0301fe\u0301rence des Mycobacte\u0301ries et de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Farinotti","sequence":"additional","affiliation":[{"name":"AP-HP, Ho\u0302pital Pitie\u0301-Salpe\u0302trie\u0300re, Service Pharmacie-Pharmacocine\u0301tique, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Veziris","sequence":"additional","affiliation":[{"name":"UPMC Universite\u0301 Paris 06, ER5, EA 1541, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75005 Paris, France"},{"name":"AP-HP, Ho\u0302pital Pitie\u0301-Salpe\u0302trie\u0300re, Laboratoire de Bacte\u0301riologie-Hygie\u0300ne, F-75013 Paris, France"},{"name":"Centre National de Re\u0301fe\u0301rence des Mycobacte\u0301ries et de la Re\u0301sistance des Mycobacte\u0301ries aux Antituberculeux, F-75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1281-1288.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.104-112.2006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1046-1054.2005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-360OC"},{"key":"e_1_3_2_6_2","first-page":"301","volume":"55","year":"2006","unstructured":"Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs\u2014worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep.55:301-305.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_7_2","first-page":"250","volume":"56","year":"2007","unstructured":"Centers for Disease Control and Prevention. 2007. Extensively drug-resistant tuberculosis\u2014United States, 1993-2006. MMWR Morb. Mortal. Wkly. Rep.56:250-253.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_8_2","first-page":"1","volume":"58","year":"2009","unstructured":"Centers for Disease Control and Prevention. 2009. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recommend. Rep.58:1-43.","journal-title":"MMWR Recommend. Rep."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1159OC"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00125705"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.01.002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/31159"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60333-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0078OC"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00541-09"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68384-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104263441706"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69573-1"},{"key":"e_1_3_2_19_2","first-page":"51","year":"1998","unstructured":"Grosset, J., and B. Ji. 1998. Experimental chemotherapy of mycobacterial diseases, p. 51-97. In P. R. Gandharam and P. Jenkins (ed.), Mycobacteria. Marcel Dekker, New York, NY.","journal-title":"Mycobacteria"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2066"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1106.040840"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2006.12.7"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61204-0"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00155708"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1768"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(98)00126-2"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2600-2603.2000"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408966102"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/507542"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800106"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.85"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200507-1072OC"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg222"},{"key":"e_1_3_2_34_2","first-page":"128","volume":"12","year":"2008","unstructured":"Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Sturm, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, and D. A. Mitchison. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuber. Lung Dis.12:128-138.","journal-title":"Int. J. Tuber. Lung Dis."},{"key":"e_1_3_2_35_2","first-page":"104","volume":"24","year":"1992","unstructured":"Sanger, F., S. Nicklen, and A. R. Coulson. 1992. DNA sequencing with chain-terminating inhibitors. 1977. Biotechnology24:104-108.","journal-title":"Biotechnology"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.69"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-005-8205-z"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107193450303"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.773"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00749-08"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3117-3122.2003"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm061"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200609-1376ED"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1508"},{"key":"e_1_3_2_46_2","first-page":"430","volume":"81","year":"2006","unstructured":"World Health Organization. 2006. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly. Epidemiol. Rec81:430-432.","journal-title":"Wkly. Epidemiol. Rec"},{"key":"e_1_3_2_47_2","unstructured":"Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for dots-plus 2001"},{"key":"e_1_3_2_48_2","unstructured":"Guidelines for the programmatic management of drug-resistant tuberculosis 2008"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1086\/505877"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00968-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00968-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:17:27Z","timestamp":1645474647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00968-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1128\/AAC.00968-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00968-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"2010-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-08-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}